Abeona Therapeutics Inc (ABEO)

NASDAQ
Currency in USD
5.0950
-0.0250(-0.49%)
Real-time Data
ABEO Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
5.03005.1800
52 wk Range
3.05008.4500
Key Statistics
Edit
Prev. Close
5.12
Open
5.17
Day's Range
5.03-5.18
52 wk Range
3.05-8.45
Volume
95.06K
Average Vol. (3m)
320.52K
1-Year Change
-32.72%
Book Value / Share
1.01
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ABEO Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
16.7500
Upside
+228.75%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

Abeona Therapeutics Inc Company Profile

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.

Abeona Therapeutics Inc Earnings Call Summary for Q4/2024

  • Abeona Therapeutics reported Q4 2024 EPS of $0.50, beating expectations of -$0.35, but missed revenue forecast of $100,000
  • Cash position improved to $98.1 million, up from $52.6 million in 2023, with R&D expenses increasing to $34.4 million
  • FDA decision on lead product expected by April 2025, with projected U.S. revenue potential exceeding $2 billion
  • Manufacturing capacity to increase for RDEB treatment, with CEO anticipating potential for two FDA approvals in 2025
  • Stock closed at $5.13, down 1.35%, despite earnings beat; analysts maintain strong buy consensus with price targets up to $25.00
Last Updated: 03/20/2025, 03:56 PM
Read Full Transcript

Compare ABEO to Peers and Sector

Metrics to compare
ABEO
Peers
Sector
Relationship
P/E Ratio
−3.9x−0.9x−0.5x
PEG Ratio
−0.100.020.00
Price / Book
5.6x0.8x2.6x
Price / LTM Sales
-5.6x3.0x
Upside (Analyst Target)
201.6%511.3%54.7%
Fair Value Upside
Unlock24.8%9.3%Unlock

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 16.7500
(+228.75% Upside)

Earnings

Latest Release
Mar 20, 2025
EPS / Forecast
0.50 / -0.35
Revenue / Forecast
-- / 100.00K
EPS Revisions
Last 90 days

People Also Watch

2.9300
DARE
+1.74%
3.075
CIFR
-3.91%
1.7079
FBIO
-0.70%
4.83
ENGN
+4.30%
3.315
ALUR
-3.91%

FAQ

What Is the Abeona Therapeutics (ABEO) Stock Price Today?

The Abeona Therapeutics stock price today is 5.095

What Stock Exchange Does Abeona Therapeutics Trade On?

Abeona Therapeutics is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Abeona Therapeutics?

The stock symbol for Abeona Therapeutics is "ABEO."

What Is the Abeona Therapeutics Market Cap?

As of today, Abeona Therapeutics market cap is 247.28M.

What is Abeona Therapeutics Earnings Per Share?

The Abeona Therapeutics EPS is -1.55.

What Is the Next Abeona Therapeutics Earnings Date?

Abeona Therapeutics will release its next earnings report on May 08, 2025.

From a Technical Analysis Perspective, Is ABEO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.